88 related articles for article (PubMed ID: 16244588)
1. Activity of cathepsin D and alpha(1)-antitrypsin in the blood serum of patients with mammary carcinoma.
Wozniak A; Mila-Kierzenkowska C; Schachtschabel DO; Wozniak B; Rozwodowska M; Drewa T; Drewa S; Sir J; Sir I; Maciak R; Krzyzynska-Malinowska E
Exp Oncol; 2005 Sep; 27(3):233-7. PubMed ID: 16244588
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.
Szajda SD; Snarska J; Jankowska A; Roszkowska-Jakimiec W; Puchalski Z; Zwierz K
Hepatogastroenterology; 2008; 55(82-83):388-93. PubMed ID: 18613372
[TBL] [Abstract][Full Text] [Related]
3. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
4. Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay.
Brouillet JP; Dufour F; Lemamy G; Garcia M; Schlup N; Grenier J; Mani JC; Rochefort H
Cancer; 1997 Jun; 79(11):2132-6. PubMed ID: 9179059
[TBL] [Abstract][Full Text] [Related]
5. The activity of cathepsin D and alpha-1 antitrypsin in hip and knee osteoarthritis.
Olszewska-Slonina D; Matewski D; Jung S; Olszewski KJ; Czajkowski R; Braszkiewicz J; Wozniak A; Kowaliszyn B
Acta Biochim Pol; 2013; 60(1):99-106. PubMed ID: 23520575
[TBL] [Abstract][Full Text] [Related]
6. [Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate].
Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):77-8. PubMed ID: 8756736
[TBL] [Abstract][Full Text] [Related]
7. [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer].
Szajda SD; Darewicz B; Kudelski J; Chlabicz M; Domel T; Chabielska E; Skrzydlewski Z
Pol Merkur Lekarski; 2005 Jun; 18(108):651-3. PubMed ID: 16124376
[TBL] [Abstract][Full Text] [Related]
8. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
9. Western blotting and enzymatic activity analysis of cathepsin D in breast tissue and sera of patients with breast cancer and benign breast disease and of normal controls.
Schultz DC; Bazel S; Wright LM; Tucker S; Lange MK; Tachovsky T; Longo S; Niedbala S; Alhadeff JA
Cancer Res; 1994 Jan; 54(1):48-54. PubMed ID: 8261461
[TBL] [Abstract][Full Text] [Related]
10. Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma.
Woźniak A; Drewa T; Rozwodowska M; Drewa G; Lambrecht W; Wiśniewska I
Neoplasma; 2002; 49(1):10-5. PubMed ID: 12044053
[TBL] [Abstract][Full Text] [Related]
11. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
12. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
[TBL] [Abstract][Full Text] [Related]
13. Ozone therapy and the activity of selected lysosomal enzymes in blood serum of patients with lower limb ischaemia associated with obliterative atheromatosis.
Tafil-Klawe M; Woźniak A; Drewa T; Ponikowska I; Drewa J; Drewa G; Włodarczyk K; Olszewska D; Klawe J; Kozłowska R
Med Sci Monit; 2002 Jul; 8(7):CR520-5. PubMed ID: 12118202
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of cathepsin D in low grade breast invasive cancer.
Lazaris AC; Theodoropoulos GE; Diamantopoulos AK; Anastassopoulos PD; Davaris PS
Anticancer Res; 1997; 17(4A):2651-5. PubMed ID: 9252696
[TBL] [Abstract][Full Text] [Related]
16. [Proteases and prostatic disease: cytosolic cathepsin D].
Gómez Díaz ME; Ruibal-Morell A; Abascal García R
Arch Esp Urol; 2001 Mar; 54(2):101-7. PubMed ID: 11341113
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics.
Hähnel R; Harvey J; Robbins P; Sterrett G
Anticancer Res; 1993; 13(6A):2131-5. PubMed ID: 8297125
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin D activity in colorectal cancer.
Chabowski A; Skrzydlewska E; Sulkowska M; Famulski W; Zalewski B; Gnojnicki I; Kisielewski W
Rocz Akad Med Bialymst; 2001; 46():38-46. PubMed ID: 11780577
[TBL] [Abstract][Full Text] [Related]
20. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
